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Photofrin accumulation in malignant and host cell populations of various
tumours
M Korbelik and G Krosl
Cancer Imaging, British Columbia Cancer Agency, Vancouver, BC, Canada.
Summary Photofrin accumulation in malignant and host cell populations of various tumours was studied by
flow cytometry analysis of cells dissociated from the tumour tissue. The transplantable mouse tumour models
included in this analysis were sarcomas EMT6, RIF, KHT and FsaN, Lewis lung carcinoma, SCCVII
squamous cell carcinoma (SCC) and slowly growing moderately differentiated AT17 SCC. An example of
spontaneous mouse adenocarcinoma was also examined. Staining with specific monoclonal antibodies was used
to identify the various cell populations present in these tumours. The main characteristic of Photofrin cellular
accumulation was a very high photosensitiser content found exclusively in a subpopulation of tumour-
associated macrophages (TAMs). Photosensitiser levels similar to or lower than in malignant cells were
observed in the remaining TAMs and other tumour-infiltrating host cells. Photofrin accumulation in malignant
cells was not equal in all tumour models, but may have been affected by tumour blood perfusion/
vascularisation. Results consistent with the above findings were obtained with SCC of buccal mucosa induced
by 9,10-dimethyl-1,2-benzanthracene in Syrian hamsters. The TAM subpopulation that accumulates by far the
highest cellular Photofrin levels in tumours is suggested to be responsible for the tumour-localised
photosensitiser fluorescence.
Keywords: photodynamic therapy; Photofrin; cellular photosensitiser level; tumour-infiltrating host cell; mouse
tumour; hamster tumour model
Photofrin, clinically the most advanced photosensitiser for
use in photodynamic therapy (PDT) of solid cancers, is an
improved and purified preparation of haematoporphyrin
derivative (HpD) (Dougherty, 1987). The tumour-localised
fluorescence of HpD and Photofrin administered systemically
is a well established phenomenon (Dougherty et al., 1992),
the nature of which is still not completely elucidated.
Measurements of the concentration of Photofrin per gram
of tumour tissue in animal models have shown that the levels
in tumours compared with the surrounding normal tissues
(e.g. muscle or skin) are similar or only slightly elevated
(Bellnier and Henderson, 1992). The difference in most cases
cannot explain the strong in situ fluorescence of the drug
which delineates the malignant lesion. This suggests that the
photosensitiser accumulates preferentially in certain tumour
elements, presumably localised in the lesion's surface.
Whereas some photosensitisers (e.g. tetrasulphonated deriva-
tives of tetraphenylporphine and aluminium phthalocyanine)
localise more abundantly in acellular tumour structures (Peng
et al., 1990), Photofrin is known to accumulate in the cellular
tumour compartment (Henderson and Fingar, 1989). For the
therapeutic potential of PDT it appears that the photo-
sensitiser level in tumour cells is more important than the
level retained in acellular tumour structures (Korbelik and
Krosl, 1995a). We have, therefore, concentrated on examin-
ing the Photofrin levels in different cellular populations
contained in solid tumours. For this purpose, we have
developed flow cytometry techniques for the determination of
photosensitiser levels in cells dissociated from tumour tissue
and are continuously working on their refinement.
In our first report, we showed (using the mouse SCCVII
tumour model) that the population of cells characterised by
the presence of the Fc receptor accumulates higher Photofrin
levels than the malignant cell population, which is FcR
negative (Korbelik et al., 1991). The FcR-positive cell
population in this tumour consists predominantly of
tumour-associated macrophages (TAMs). Our subsequent
goal was to identify and measure the photosensitiser content
in all major cell populations that can be found in solid
tumours. The results obtained with a model of mouse
fibrosarcoma (FsaR) were recently reported (Korbelik and
Krosl, 1995b). They show that, with respect to Photofrin
accumulation, a subpopulation of TAMs exceeds by far
malignant cells and all other major host cell types present in
this tumour. How representative this finding (with one type
of transplantable tumour) is for different types of solid
cancers remains to be established. We have suggested
(Korbelik and Krosl, 1995a,b) that removing debris and
substances that may be detrimental to the tumour, which will
include entrapping the photosensitiser material, is a common
physiological role of TAMs in various cancerous lesions.
Hence, it is important to determine whether this factor (or
some other elements) dominates the Photofrin accumulation
in different types of tumours. Carcinomas and sarcomas
should be examined at different degrees of differentiation,
including the autochthonous tumours (carcinogen induced or
spontaneous). In this report, we present the results on cellular
Photofrin distribution obtained with a series of transplan-
table murine carcinomas and sarcomas, including a model of
slowly growing moderately differentiated carcinoma and an
example of the spontaneous murine adenocarcinoma. The
data obtained with squamous cell carcinomas (SCCs) induced
by 9,10-dimethyl-1,2-benzanthracene (DMBA) in the mucosa
of hamster cheek pouch are also shown.
Materials and methods
Tumour models
The transplantable tumours used in this study were implanted
subcutaneously in syngeneic female mice 9-11 weeks of age.
Growing in the C3H/HeN mice were KHT sarcoma
(Kallman et al., 1967), fibrosarcomas RIF (Twentyman et
al., 1980), FsaR and FsaN (Volpe et al., 1985), and SCC
models SCCVII (Suit et al., 1985) and AT17. Mice strains
Balb/c and C57BL were used for the EMT6 mammary
sarcoma (Rockwell et al., 1972) and Lewis lung carcinoma
(LLC) (Sugiura and Stock, 1955) respectively. These tumours
ranged from poorly immunogenic (e.g. SCCVII) to strongly
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October 1995immunogenic (e.g. EMT6). In vitro cultured cells were used
for implantation of FsaR and FsaN tumours, as described
previously (Korbelik and Krosl, 1995b). The other tumours
were implanted directly from maintenance tumours. The
trocar method for implanting small (approximately 1 mm3)
tumour fragments was required for the AT17 carcinomas,
whereas the injection of 3-5 x 105 enzymatically dissociated
cells was used with other tumour models. In contrast to the
other tumours, which were rapidly growing and represented
poorly differentiated sarcomas and carcinomas, the slowly
growing AT17 carcinoma was moderately differentiated (as
established by a histopathological examination). This tumour
model was developed by Dr J Kummermehr (GSF,
Neuherberg, Germany). An early serial passage (provided
by Dr Al Minchinton) was used in this study.
A primary tumour that arose spontaneously on the left
side of the lower abdominal area of a female C3H/HeN
mouse (retired breeder) was also included in the study.
Examination of histological sections and electron microscopy
preparations from a fragment of the tumour taken after the
excision revealed that this was a moderately differentiated
adenocarcinoma.
All the tumours were used for experiments when they
attained a size of 150-250 mg wet weight. The transplantable
tumours reached the required size 12 days after implantation,
except for the AT17 carcinomas, which were implanted 10
weeks earlier. The tumour-bearing mice were administered
Photofrin (25 mg kg-') by intravenous injection. Photofring
(porfimer sodium) was produced and provided by QLT Photo
Therapeutics (Vancouver, BC, Canada).
The carcinogen DMBA (Sigma Chemical, St. Louis, MO,
USA) was used for the induction of SCCs in the buccal
pouch epithelium of outbred Syrian golden hamsters.
Following the procedures described by Hemming et al.
(1993), the DMBA-impregnated silicone-coated sutures were
inserted submucosally into the right cheeks of 7-week-old
male hamsters. Two weeks after the implant, the site was
painted with the DMBA solution (10 mg ml-1) in mineral oil,
which was repeated weekly until a papillomatous lesion
appeared. These lesions progressed to microinvasive cancers
within 14-20 weeks after the suture implantation, and at this
stage they were used for experiments. The hamsters were
given Photofrin intraperitoneally using the same dose as with
tumour-bearing mice (25 mg kg-').
Flow cytometry
Tumour-bearing animals were sacrificed 24 h after receiving
Photofrin. The excised tumours were minced with scalpels
and then enzymatically dissociated into a single-cell
suspension as described previously (Korbelik, 1993). The
viability of these cells ranged between 75% and 95%,
showing some variation depending on the tumour model,
but in most cases was over 90%. The cell yield varied
between 4.5 x 107 and 2.5 x 108 cells per gram of tumour
tissue depending on the tumour model.
In most experiments, the hearts were also excised from the
mice immediately after the sacrifice. In the experiments with
the hamster tumour model, hearts and normal mucosa tissue
from the left cheek pouch were also used in the analysis.
These tissues were minced and enzymatically digested using
the same procedure as with tumour tissues. The erythrocytes
present in suspensions of the heart muscle cells were removed
by lysis, as described previously (Korbelik and Krosl, 1995b).
The single-cell suspensions obtained from tumour tissues
were resuspended in Hanks' balanced salt solution (HBSS)
supplemented with 2% fetal bovine serum (FBS) and
separated into aliquots (1 x 106 cells each) for staining with
different combinations of monoclonal antibodies (MAbs).
Each staining was performed with a pair of fluorescein
isothiocyanate (FITC)- and phycoerythrin (PE)-conjugated
MAbs. The MAbs used were directed against the following
mouse antigens: CD45 (pan-leucocyte marker), F4/80
(marker for mature macrophages), GRI (myeloid cell
antigen), CD3e (T-lymphocyte marker), CD25 [interleukin
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(IL)-2 receptor], CD31 (PECAM-1 adhesion molecule) and I-
Ek (MHC class II molecule specific for C3H mice). The anti-
F4/80 MAb was purchased from Serotec Canada (Toronto,
Ontario, Canada), whereas the other MAbs were obtained
from PharMingen (San Diego, CA, USA). The single-cell
suspensions obtained from DMBA-induced hamster SCC
were stained only with FITC-conjugated mouse anti-hamster
IgG (PharMingen).
The procedure for MAb staining and flow cytometry
analysis was previously described in detail (Korbelik and
Krosl, 1995b). Briefly, a 30 min incubation on ice (0°C) with
appropriate MAb dilutions was followed by washing the cells
twice in HBSS plus 2% FBS before flow cytometry. In most
cases the staining was preceded by a 3 min exposure to the
FcBlock (PharMingen) in order to block the Fc receptor-
mediated non-specific binding of MAbs. As discussed
previously (Korbelik and Krosl, 1995b), an additional
measure to exclude the contamination of other cell
populations with non-specifically stained TAMs is to identify
them as F4/80-. For example, by staining with anti-CD3e-PE
combined with anti-F4/80-FITC the T-lymphocyte popula-
tion was identified as CD3s+F4/80-.
A dual laser apparatus Coulter Epics Elite ESP (Coulter
Electronics, Hialeah, FL, USA) was used for flow cytometry.
The UV laser served for the excitation of Photofrin
fluorescence, which was directed through a 610 nm longpass
filter. The staining with MAbs was visualised by FITC or PE
fluorescence, both excited by a 488 nm laser and recorded
after passing through the appropriate bandpass filters. Also
recorded were the forward and side light scatter (FS and SS)
for each cell. Additionally, the 'time of flight' parameter was
used for gating out cell doublets. Usually, 104 cells were
analysed for each sample, but in some cases up to 5 x 104 cells
were included to facilitate the identification of the
CD31 +CD45 - population. The dead cells in tumour cell
suspensions are easily distinguished by their decreased FS
and SS values, and were gated out in flow cytometry analysis.
Our experience in the fluorescence and staining of dead and
dying cells was described previously (Krosl et al., 1995).
Tumour-bearing mice (or hamsters) not administered
Photofrin were included in all experiments, so that the
tumour or normal tissue derived single-cell suspensions not
containing the photosensitiser could be obtained and used as
a control for cell autofluorescence >610 nm. In a previous
report (Korbelik and Krosl, 1995b) we showed that this
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Figure 1 A representative example of the range of Photofrin
cellular levels within a mouse tumour. Photofrin (25mgkg-1, i.v.)
was administered to an AT17 carcinoma-bearing C3H/HeN
mouse 24h before the tumour was excised and enzymatically
dissociated into a single-cell suspension. The single-event dot plot
presents Photofrin fluorescence intensity (in arbitrary units) in
individual cells on the abscissa vs cellular light SS signal on the
ordinate.
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autofluorescence had much lower intensity than cellular
Photofrin fluorescence (when a dose of 25 mg kg-' is
administered) and cannot affect the measurement of
photosensitiser content in cells. Additional control experi-
ments (Korbelik et a!., 1991; Korbelik, 1993; Korbelik and
Krosl, 1995b) verified that the enzymatic digestion procedure
does not induce significant (nor cell type selective) loss of
Photofrin from the cells derived from tumour and other
tissues.
Results
Cellular Photofrin levels in various tumours are invariably
characterised by a marked heterogeneity exemplified in
Figure 1. The single event dot plot (with dots representing
individual cells) shows the intensity of cellular Photofrin
fluorescence in relation to the light SS signal. The SS value
reflects the cell size and granularity. It can be seen that the
cellular Photofrin levels spread over 4 logs in this non-
selected population from a mouse AT17 carcinoma. Very
similar pictures were obtained with all samples that we
analysed, regardless of the tumour model. The cells were in
all cases dissociated from the tumour tissue that was excised
24 h after the animal received Photofrin (25 mg kg-', i.v.).
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The main origin of heterogeneity in cellular Photofrin
levels appears to be the presence of tumour-infiltrating
leucocytes (TILs). The representative examples of Photofrin
cellular distribution in nine different mouse tumour models:
sarcomas EMT6, KHT, RIF, FsaR and FsaN, carcinomas
AT17, SCCVII, LLC, and including an adenocarcinoma that
arose spontaneously in a female C3H/HeN mouse, are shown
in Figure 2. Before flow cytometry analysis, the cell
suspensions were stained with PE-conjugated anti-mouse
CD45 (panleucocyte marker). According to PE fluorescence,
each cell suspension can be separated into populations of
negatively stained malignant cells and postively stained TILs.
The resulting dot plot can serve as a characteristic
'fingerprint' for each type of tumour, illustrating the extent
of leucocyte infiltration and the pattern of Photofrin
accumulation in the leucocyte population relative to the
malignant cells. It is evident that there are considerable
variations in the leucocyte content among the tumours
depicted in Figure 2. However, common to all these tumours
is the presence of a leucocyte subpopulation (of variable size)
that excels in Photofrin accumulation compared with all
other cells present in the tumour, including malignant cells.
Individual cells in this leucocyte fraction reach 50 or more
times higher Photofrin levels than the malignant cells.
Selection and analysis of such leucocyte fractions are
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Figure 2 Photofrin distribution among malignant and host immune cell populations of different types of mouse tumours.
Representative examples are shown of single-cell suspensions obtained from the indicated tumours that were growing in mice treated
with Photofrin as described in Figure 1. Before flow cytometry, the cells were stained with PE-conjugated anti-mouse CD45 (a pan-
leucocyte marker). The fluorescence ofcell-bound PE-CD45 on the ordinate is plotted against photosensitiser fluorescence >610nm
on the abscissa (both in arbitrary units per cell).
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illustrated in Figure 3. In addition to anti-CD45-PE, the cells
were stained with FITC-conjugated anti-mouse F4/80 (the
marker for mature macrophages). The gates were set to select
the cells with Photofrin levels above the highest photo-
sensitiser content of cells from the malignant cell population.
Both 'selected' (gate B) and remaining cells (gate A) were re-
examined for FITC fluorescence. It can be noted that all the
selected cells are F4/80+, i.e. they are TAMs. The remaining
cells contain not only F4/80- population (malignant cells and
leucocytes other than TAMs), but also F4/80+ cells, i.e.
TAMs with Photofrin levels similar to or lower than in
malignant cells.
Although such selection by gating based on Photofrin
levels is very valuable for the analysis of Photofrin cellular
distribution in tumours, it does not provide information on
the nature of this TAM subpopulation characterised by
exceedingly efficient accumulation of the photosensitiser. Our
search for markers that would distinguish such TAM
subpopulations from TAMs that accumulate lower photo-
sensitiser levels resulted in the identification of the CD25
antigen (the IL-2 receptor) as a marker for TAMs of the
FsaR tumour (Korbelik and Krosl, 1995b). The staining
combination anti-F4/80-FITC plus anti-CD25-PE was exam-
ined with other mouse tumour models and the examples of
three tumour types are shown in Figure 4. Similarly, as with
the TAMs of FsaR tumours, a clear linear correlation
between the intensity of CD25 staining and Photofrin content
can be seen in TAMs of LLC and KHT tumours. However,
the example with the EMT6 tumour illustrates that in some
tumour types this linearity may not extend to all TAMs.
Although in this tumour the TAM subpopulation with the
highest Photofrin levels exhibits the maximal CD25 staining,
there are other TAMs present with somewhat lower
photosensitiser levels that show equally good CD25 staining.
So far, we were unable to identify other markers that
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would select the TAM subpopulation accumulating the
highest photosensitiser levels in tumours. For instance, we
examined the staining with the antibody to the MHC class II
antigen. The results were unsatisfactory because there was no
direct correlation between the intensity of TAMs staining for
this antigen and accumulated Photofrin levels (not shown).
The average values for the cellular Photofrin content in
different types of TILs relative to the photosensitiser content
in malignant cells are shown in Figure 5 for various types of
murine carcinomas (top series) and sarcomas (lower series).
Included in that analysis are average Photofrin levels in
selected cells, gated on the basis of their extremely high
photosensitiser content (as shown in Figure 3). In addition to
TAMs, the leucocytes infiltrating the tumours examined in
this study were found to consist of two major cell types, T
lymphocytes (F4/80- cells stained positively for the common
T cell antigen CD3) and other myeloid cells (F4/80- cells
stained positively for the myeloid differentiation antigen
GRI). Morphological examination suggests that a vast
majority of GRI+F4/80- cells are monocytes or immature
macrophages. The level of other immune cells that may be
present (natural killer cells, B lymphocytes, mast cells) is
much less than 1% of the total cell content, which precludes
any significant role for these cells in the overall Photofrin
tumour localisation. For each tumour model analysed in
Figure 5, a pie graph is inserted depicting the average per
cent distribution ofmajor cell populations. The pie graphs re-
emphasise in a more accurate way the impression from
Figure 2 of the diversity of cellular composition of tumours.
Whereas in AT17, KHT and RIF the leucocytes represent a
minor fraction (30% or less), in EMT6 and especially FsaN
tumour the TAM population is predominant. The GRI+F4/
80- and CD3+F4/80- populations are minor in all tumours
(1-5%, except in LLC which has on average 9% of T cells).
Despite considerable differences in cellular content, the
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Figure 3 An example of selection and analysis of cellular fraction containing the highest Photofrin levels among cells contained in
a Lewis lung carcinoma. A dot plot graph similar to those from Figure 2 is shown on the left, with the indicated gates B (cells
containing Photofrin levels higher than the malignant cells exclusively) and A (the remaining cells). The cells from these two gates
are presented in additional graphs plotted to show their staining with FITC-conjugated anti-F4/80. Further details are as explained
in Figures 1 and 2.
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Figure 4 Relation between Photofrin accumulation and IL-2 receptor expression in TAMs (F4/80+ cells) from Lewis lung
carcinoma (LLC), KHT sarcoma and EMT6 sarcoma. Single-cell suspensions obtained from representatives of these three tumour
types were stained with the MAb combination CD25-PE plus F4/80-FITC before flow cytometry. Further details are as explained in
Figures 1 and 2.Photofrin cellular distribudon In tumours
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general pattern of Photofrin cellular accumulation is very
similar in these tumours. In all cases the highest Photofrin
levels are found in a subpopulation of TAMs. In comparison
with the malignant cell population Photofrin content in
selected cells (gated as illustrated in Figure 3, and found to be
exclusively TAMS in all these tumours) is 8-22 times higher,
depending on the tumour model. The staining of TAMs with
anti-CD25 varied in its efficacy to distinguish TAMs from the
selected populations from other TAMs. The F4/80+CD25+
cells matched the selected cells most closely in the SCCVII
tumour, whereas with other tumour models this staining
included different proportions of non-selected TAMs with
somewhat lower Photofrin levels. The greatest disparity can
be observed with EMT6 and FsaN tumours, in which
relatively large fractions of TAMs that accumulate moder-
ately high Photofrin levels stain strongly for the CD25
antigen. The selected cells represented from 10% to 20%
(EMT6, FsaN, LLC) to over 50% (AT17, FsaR) of all
TAMs.
Whereas the F4/80+CD25+ cells accumulated, in all cases,
at least several times higher Photofrin levels than the
malignant cells, photosensitiser levels in remaining TAMs
(F4/80+CD25-) were similar or somewhat lower than the
average level in malignant cells. Elevated Photofrin levels
were never seen in TILs other than TAMs. The photo-
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sensitiser content in GRl +F4/80- and CD3+F4/80- cells
ranged generally between 50% and 80% of that in malignant
cells.
The primary (non-transplanted) adenocarcinoma (shown
in Figure 2) was also analysed in detail. The pattern of
Photofrin distribution among the main cellular populations in
this tumour was not different from that in transplantable
mouse tumour models. Compared with the level in the
malignant cells Photofrin content was 33 and 25 times higher
in the selected and in the F4/80+CD25+ population
respectively. This tumour contained 68% CD45- cells, 3%
F4/80+CD25+ and 10% F4/80+CD25- cells. The selected
cells represented 33% of all TAMs.
Besides immune cells non-immune host cells such as
endothelial cells and normal fibroblasts are also found in
solid tumours. In terms of total cellular content they (in
tumour models examined in this study) represent a very
minor fraction (<<1I%), which cannot have a significant
role in the tumour localisation of photosensitisers. However,
it was of interest to examine Photofrin levels in the
endothelial cell population because vascular effects are
known to be of a critical importance in the anti-tumour
effect of PDT (Henderson and Dougherty, 1992).
The endothelial cells in tumour cell suspensions were
identified as CD31+CD45-, i.e. leucocytes that may stain
Figure 5 Comparison of the Photofrin levels in the major TIL populations with those in malignant cells for a series of mouse
carcinomas (top series) and sarcomas (lower series). The cell populations examined are the: (i) 'selected' cells (exemplified by the
gate B in Figure 3), (ii) TAMs expressing IL-2 receptor (F4/80+CD25+), (iii) remaining TAMs (F4/80+CD25-), (iv) myeloid cells
other than TAMs (GRI+F4/80-) and (v) T lymphocytes (CD3s+F4/80-). Relative contents of these populations and malignant
cells (CD45-) for the tumour models are depicted in the inserted pie graphs. Photofrin administration was as described in Figure 1.
The data represent average values from six or more tumours; bars are+s.d.Photofrin cellular distribution in tumours
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positively to the CD31 antigen (PECAM-1 adhesion
molecule) were excluded. A possible contamination with
platelets (which are also CD31 positive) was eliminated by
gating for cell-size objects. Still, the isolation of a pure
endothelial cell fraction proves to be a challenging task. The
CD31+CD45- population ranged only from 0.1% to 0.2% of
the total cell population in tumours examined in this study,
which makes it difficult to eliminate the risk of contamination
with other cell types that could affect the measurement. The
results of flow cytometry analysis represented by data
obtained with AT17 and SCCVII tumours are shown in
Figure 6. Despite the concerns raised above, the fact that the
results consistently showed no statistically significant
difference in Photofrin level between CD31+CD45- and
CD45- cell populations appears to be a reasonable indication
that there is no substantial selectivity in photosensitiser
accumulation in the endothelial cells of tumour vasculature.
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In addition to tumour tissue, hearts were also collected
from the same mice. Photofrin content in the heart muscle
cells dissociated by the enzymatic treatment was determined
by the same flow cytometry technique. The results of the
comparative analysis of photosensitiser levels in malignant
cells (CD45-) ofvarious tumours and heart muscle cells from
the same animals are presented in Figure 7. The Figure
demonstrates that the selectivity ofPhotofrin accumulation in
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Figure 6 Comparison of Photofrin levels in the endothelial cell
fraction with those in the malignant cells from mouse squamous
cell carcinoma models AT17 and SCCVII. The single-cell
suspensions obtained from tumour tissues were stained with the
MAb combination CD31-FITC plus CD45-PE so that the
endothelial cells can be identified as CD31 +CD45-. Further
details are as in Figure 5.
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Figure 7 Comparison of the Photofrin levels in malignant cells
(CD45-) with those in heart muscle cells (from the same animal)
in a series of mouse tumour models. Most tumours (the
exceptions were LLC and EMT6) were growing in the same
mouse strain (C3H/HeN). Other details are as in Figure 5.
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Figure 8 Photofrin distribution among cells of DMBA-induced
hamster SCC, and the relation to photosensitiser levels found in
some normal tissue cells. The tumours and normal tissues were
excised 24h after the animals received Photofrin (25mgkg- ,
i.p.). (a) A representative example of Photofrin fluorescence in
cells from a hamster SCC stained with FITC conjugated anti-
hamster IgG (the positively stained, i.e. FcR+ cells are delineated
by the gate A). (b) Comparison of Photofrin levels in FcR+ cells
(i.e. the TAM population), as well as those in the normal buccal
mucosa and heart muscle cells, with the Photofrin levels in the
malignant cell fraction (FcR-); the data represent the average
values (±s.d.) from five SCC-bearing hamsters.
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malignant cells related to heart muscle cells (representing
normal tissue cells) varies with different tumour models. With
most of the examined tumours, the ratio of Photofrin content
for CD45- cells-heart muscle cells was between 1 and 2.
However, in some tumours this ratio was either considerably
higher (FsaN, AT17) or lower (RIF). The difference between
tumours with the highest and lowest selectivity of Photofrin
accumulation (FsaN compared with RIF) was almost 4-fold.
Both these tumour types grow in the same mouse strain
(C3H/HeN).
Cellular levels of Photofrin were also examined in DMBA-
induced SCC growing in the cheek pouch of Syrian hamsters,
which is one of the best characterised models for carcinogen-
induced carcinoma (Salley, 1954). Hamsters were adminis-
tered Photofrin intraperitoneally, using the same dose as in
tumour-bearing mice (25 mg kg-'), and were sacrificed 24 h
later. Tumour tissue, normal mucosa tissue from the opposite
cheek pouch and hearts were then taken for flow cytometry
analysis. Since monoclonal antibodies to the hamster cell
membrane antigens (equivalent to those employed in the
mouse experiments) were not available to us, the FITC-
conjugated anti-hamster IgG was used to stain the tumour
cell suspensions. This staining separates TAMs (which are
FcR positive) from the malignant cell population (FcR-
cells), as shown previously in mouse tumour models
(Korbelik et al., 1991).
An example of Photofrin distribution among the cells of
hamster SCC is shown in Figure 8a. In the same way as with
mouse tumour models considerable heterogeneity in the
photosensitiser cellular levels is evident. Another similarity
to mouse tumours is the existence of a fraction of host
immune cells characterised by elevated Photofrin content
compared with the malignant cell fraction. The hamster SCC
examined in this study contained, on average, three times
more FcR- than FcR+ cells. The results ofcellular Photofrin
measurement (Figure 8b) show over eight times higher
photosensitiser levels in FcR+ cells than in FcR- cells. On
the other hand, the average Photofrin level in the latter cell
population was approximately two and 2.5 times higher than
in the cells of buccal mucosa and the heart muscle
respectively.
Discussion
A series of tumour models were used in this work for the
investigation of Photofrin distribution among major cellular
populations present in these lesions. The results confirmed
our recently reported findings with a mouse fibrosarcoma
model (Korbelik and Krosl, 1995b). Most of the examined
tumour models were rapidly growing, poorly differentiated,
transplantable carcinomas and sarcomas (which are the most
practical for experimental work). However, also included was
a model of slowly growing moderately differentiated SCC
(AT17). In addition, the results are shown with one example
of a primary, autochthonous tumour (moderately differen-
tiated adenocarcinoma) that arose spontaneously in a female
C3H/HeN mouse. Moreover, the results in the model of
carcinogen-induced hamster SCC (although less detailed
owing to the lack of appropriate anti-hamster MAbs)
essentially agree with the findings in mouse tumour models.
All the above observations suggest that Photofrin accumula-
tion in cells contained in solid cancers does not depend on
the: (i) species (mouse or hamster); (ii) type of cancer
(carcinoma or sarcoma); (iii) degree of differentiation; (iv)
tumour origin (transplanted or either carcinogen induced or
spontaneous autochthonous tumours); (v) cellular composi-
tion of the tumour; (or vi) tumour immunogenicity. The fact
that the results with the hamster tumour model appear to be
no different from those with mouse tumours indicates that
the lipoprotein distribution in the blood has no marked effect
on the character of Photofrin accumulation in tumours.
Humans and hamsters have a predominantly low-density
lipoprotein (LDL) blood count, whereas mice have a high-
density lipoprotein (HDL) as the most abundant blood
lipoprotein (Chapman, 1986).
The main characteristics of cellular localisation of
Photofrin in tumours and surrounding normal tissues can
be summarised as follows:
(1) Cellular Photofrin levels in tumours are highly hetero-
geneous, which originates mostly from the presence of
various types of TILs. Another factor is the decreased
Photofrin accumulation in cells, with their increasing
distance from the tumour vasculature (Korbelik and
Krosl, 1994).
(2) A subpopulation of TAMs is the cell fraction that
accumulates (by far) the highest Photofrin levels in all
tumours. The degree of selective accumulation of the
photosensitiser in this fraction varies in different tumour
types from less than 10-fold to greater than 20-fold higher
than the average level in the malignant cells.
(3) Remaining TAMs and other TILs accumulate similar or
up to 2.5 times lower Photofrin levels than malignant cells.
(4) Photofrin content in the endothelial cells contained in
tumours is similar to the range found in malignant cells.
(5) Photofrin accumulation in malignant cells shows a limited
selectivity, relative to the normal muscle cells (exemplified
by the heart muscle cells), which also varies depending on
the tumour type.
The cellular Photofrin fluorescence intensity generally does
not correlate with the cell size (Figure 1), although this may
be a relevant parameter with some of the cells contained in
tumours. A smaller size may contribute to the lower level of
Photofrin in tumour-infiltrating monocytes and lymphocytes
relative to malignant cells. The TAM subpopulation showing
the highest accumulation of the photosensitiser is also
characterised by their increased size compared with other
TAMs (Korbelik and Krosl, 1995b).
The results of Photofrin measurement in endothelial cells
(Figure 6) support the finding of in vitro studies that suggest
that these cells do not exhibit preferential uptake of
photosensitisers (Gomer et al., 1988).
Comparative analysis of Photofrin accumulation in
malignant cells of various tumours (Figure 7) reveals that
the selectivity of localisation of the photosensitiser is not the
same in all types of cancerous lesions. Different types of
tumours growing in syngeneic inbred mice siblings can
accumulate markedly different Photofrin levels not only in
malignant cells, but the overall cellular levels can be higher or
lower depending presumably on the blood perfusion/
vascularisation of the tumour as well.
The TAM subpopulation that excels above all other cell
populations in tumours (and in surrounding normal tissues)
in Photofrin accumulation can be the determinant of tumour
localised photosensitiser fluorescence referred to in the
introduction. This is supported by the evidence that in
human malignancies, TAMs preferentially localise in the
lesion's periphery (Bucana et al., 1992; Svennevig and Svaar,
1979).
Further implications of the above described Photofrin
distribution in malignant and host cell populations contained
in tumours, e.g. the relevance with respect to the outcome of
PDT, were elaborated on in our related papers (Korbelik and
Krosl, 1995a,b).
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